Lotus Pharmaceutical Announces Acquisition of Sandoz AG’s Philippines Business, Strengthening Its Presence in Southeast Asia

Taipei, Taiwan, 02 April 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that it has entered into an agreement to acquire Sandoz AG’s Philippines business. Subject to closing conditions, the acquisition is expected to be completed in Q2 2026.

Upon completion, Lotus will undertake the sales and marketing of existing products of Sandoz Philippines. The acquired portfolio is primarily focused on generics and biosimilars, covering a broad range of therapeutic areas, including cardiovascular (~40%), oncology (~25%), anti-infectives (~10%), and other categories. The business will provide Lotus a strong and established platform in one of Southeast Asia’s fastest-growing pharmaceutical markets.

Following the acquisition, approximately 80 employees from Sandoz Philippines are expected to join Lotus, significantly strengthening the Company’s local commercial capabilities and expanding its footprint across hospital and specialty care channels in the Philippines.

Petar Vazharov, Chief Executive Officer of Lotus Pharmaceuticals, commented: " This acquisition represents another important step in Lotus’ strategy to expand its presence across Southeast Asia and reinforce our position in high-value generics and biosimilars. By integrating Sandoz’s Philippines business into our operations, we will gain a scaled commercial platform, a diversified therapeutic portfolio, and a talented local team. This transaction aligns with our long-term ambition to build a leading global pharmaceutical company while improving patient access to quality medicines."

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.